Abstract

Advances in the Diagnosis and Management of Ankylosing Spondylitis: From Traditional to Biological Therapies

Author(s): Alice Johnson*

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the axial skeleton, characterized by pain and stiffness in the spine and sacroiliac joints. It is part of a broader group of diseases known as spondyloarthropathies. Early diagnosis and management are crucial to reducing disease progression, improving functional outcomes, and enhancing the quality of life for patients. While nonsteroidal anti-inflammatory drugs (NSAIDs) have historically been the cornerstone of AS management, significant advances in the development of biologic therapies have revolutionized the treatment landscape. This review explores the current advances in the diagnosis and management of AS, including updated diagnostic criteria, imaging techniques, and biologic therapies, such as tumor necrosis factor inhibitors (TNFi) and interleukin-17 (IL-17) inhibitors. It also examines the challenges in managing AS and the future direction of treatment, emphasizing the role of personalized medicine in optimizing therapeutic outcomes.